Positive Lupus Anticoagulant, Awaiting APS Confirmation
Do you have to wait for full APS confirmation before trying to conceive again?
Not necessarily — ESHRE guidance recommends low-dose aspirin plus heparin after three or more pregnancy losses, tied to loss history rather than a confirmed APS diagnosis specifically, and aspirin can reasonably start before conception with heparin added once pregnancy is confirmed. That's a real, guideline-supported question worth bringing to your reproductive immunologist rather than assuming a full stop is the only responsible path.
After recurrent pregnancy loss, a positive lupus anticoagulant result can feel like both a relief (finally, a possible explanation) and a new source of anxiety — because antiphospholipid syndrome (APS) diagnosis requires a second confirmatory test at least 12 weeks after the first. For patients who don't conceive quickly, that waiting period can feel like it's costing precious fertile windows on top of everything already lost to years of trying. Here's what's actually true about this timeline, and why the standard advice to simply "wait for confirmation" may not be the full picture.
How APS Diagnosis Actually Works
Antiphospholipid syndrome is diagnosed using classification criteria that require two separate things to both be present: a clinical criterion and a laboratory criterion. The clinical criterion includes things like three or more consecutive pregnancy losses before 10 weeks, or one loss after 10 weeks, or a history of blood clots. The laboratory criterion requires a positive test — lupus anticoagulant, anticardiolipin antibodies, or anti-β2-glycoprotein antibodies — on two separate occasions, at least 12 weeks apart. This 12-week gap exists because antiphospholipid antibodies can transiently appear due to infections or other temporary triggers, and the repeat testing is designed to confirm the antibodies represent a persistent, genuine finding rather than a temporary blip.
This is a real and medically important distinction, and it's why the wait exists. But it's worth understanding what this waiting period is actually for: confirming a formal diagnosis. It is not, by default, the same thing as "you cannot begin any protective treatment until the diagnosis is fully confirmed" — and that distinction matters enormously for anyone facing a fertility timeline pressure on top of this wait.
The Overlooked Detail: Treatment Isn't Always Gated on Full Confirmation
This is the piece that often gets lost in the anxiety of "waiting to be diagnosed." Professional guidelines on recurrent pregnancy loss treatment are, in some respects, more permissive than the diagnostic criteria alone might suggest. ESHRE's recurrent pregnancy loss guideline states plainly that low-dose aspirin combined with heparin is recommended after three or more pregnancy losses — notably, this recommendation is tied to loss history, not to a confirmed APS diagnosis specifically. Separately, clinical guidance addressing exactly this patient profile — a history of three or more losses under 10 weeks — states that aspirin should be started before conception, with heparin or low-molecular-weight heparin (LMWH) added once pregnancy is confirmed, rather than before.
Put together, this creates a genuinely different picture than "wait until October, then start trying." A patient with three or more losses and a single positive antiphospholipid antibody result already meets real, guideline-referenced criteria for starting protective treatment — specifically low-dose aspirin — ahead of formal confirmatory testing, with heparin added only once a pregnancy is actually achieved (heparin initiation before conception isn't supported by the evidence base, so that piece genuinely does wait for a positive test, but aspirin doesn't have to).
This isn't an unusual or fringe approach. Clinical trial protocols studying antiphospholipid-related pregnancy loss explicitly enroll patients who have only one positive lab result while the confirmatory second test is pending — treating based on strong clinical suspicion plus a single positive result is a recognized, accepted approach in this field, not something a patient would be asking their doctor to do off-label or unusually.
The Question Worth Bringing to Your Reproductive Immunologist
Given this, the more useful question to bring to an upcoming appointment isn't "should I wait until my confirmatory test comes back before trying" — it's something closer to: "Given that I already meet the clinical criteria with my loss history, and I have one positive antibody result, would you start me on prophylactic low-dose aspirin now, and add LMWH once I have a positive pregnancy test, rather than waiting for full confirmatory testing before beginning any treatment?"
This reframes what often feels like a binary choice — wait safely, or try unprotected — into a real third option: trying with a protective plan already in place, even before the formal diagnosis is confirmed. Not every RI will necessarily agree to this depending on the fuller clinical picture, but it's a legitimate, guideline-supported question to ask directly, rather than assuming the only responsible path is a full stop until diagnostic confirmation arrives.
A Necessary Caveat: Natural Killer Cell Testing Is a Different, More Unsettled Story
Recurrent pregnancy loss workups increasingly include natural killer (NK) cell testing, and it's important to be honest that this sits on much less settled scientific ground than antiphospholipid antibody testing and treatment. ASRM's most recent recurrent pregnancy loss guidelines explicitly state that routine immune testing panels — including NK cell testing (both circulating and mucosal), HLA typing, and cytokine profiles — are not recommended, citing inconsistent testing methodologies and insufficient evidence connecting results to outcomes or to treatment benefit. ESHRE's guideline reaches a similar conclusion, finding no high-quality evidence to support NK cell testing or NK-directed immunotherapy (such as IVIG, intralipid infusions, or corticosteroids) as part of standard recurrent loss care.
This doesn't mean NK cell findings are meaningless, or that a reproductive immunologist recommending this testing is acting outside reasonable clinical judgment — particularly in complex, multi-factor cases where standard workups haven't yielded clear answers. But it does mean that decisions built around NK cell results deserve to be weighed with real awareness that this area lacks the kind of consensus and evidence base that antiphospholipid antibody treatment has. If NK cell findings are part of a broader treatment plan, it's worth understanding which parts of that plan rest on strong evidence (aspirin and heparin for antiphospholipid-related loss) and which rest on a more individualized, less standardized clinical judgment call (NK-cell-directed treatment).
Where Karyotype Testing Fits Into the Timeline
Parental karyotype testing — checking both partners' chromosomes for balanced translocations or other structural variations that could explain recurrent loss — is a valuable and standard part of a thorough RPL workup. But it's worth knowing that this result is generally more useful for explanatory and counseling purposes (understanding "why," and informing decisions about options like PGT-A testing in a future IVF cycle) than as something that needs to gate whether a couple tries to conceive naturally in the interim. Unless there's a specific reason to expect an abnormal result requiring immediate management change, waiting for karyotype results before trying again isn't typically a necessary precondition — it's a parallel piece of information gathering, not usually a treatment gate. That is the focus of Recurrent Pregnancy Loss.
Bringing It Together
Facing recurrent pregnancy loss while multiple diagnostic pieces are still pending is genuinely difficult to navigate, especially when fertility itself doesn't come quickly or predictably. The key reframe worth taking into any upcoming appointment: a formal APS diagnosis and the ability to start protective treatment aren't necessarily the same milestone. Guidelines support starting aspirin based on loss history and a single positive antibody result, with heparin added once pregnancy is achieved - meaning "wait for full confirmation" and "try this cycle" may not have to be an either/or choice. It's worth asking directly — something we help patients across Long Island think through — rather than assuming the answer. More on that here: MTHFR and recurrent pregnancy loss. We go deeper into this in laparoscopy after recurrent pregnancy loss.
This article is for general educational purposes and isn't a substitute for individualized guidance from your own physician or reproductive immunologist. Decisions about starting treatment, testing timelines, and trying to conceive should be made directly with your care team, based on your complete clinical picture.
East to West Fertility, is a metabolic and immune-focused fertility practice in Huntington, NY, serving Long Island, NYC, and beyond. We help patients navigate complex recurrent pregnancy loss workups, including antiphospholipid syndrome and immune-related factors, alongside your reproductive immunologist and REI care. Learn more about our Metabolic & Immune Fertility Evaluation at easttowestfertility.com or call 631-416-4940.
References:
"Antiphospholipid Syndrome." StatPearls, NCBI Bookshelf.
"ESHRE guideline: recurrent pregnancy loss." Human Reproduction Open.
"New ASRM Recurrent Pregnancy Loss Guidelines 2026: What They Mean for You."
